A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): Interim analysis.

Daniel M. Geynisman,Philip Abbosh,Eric A. Ross,Matthew Zibelman,Pooja Ghatalia,Fern Anari,Katherine Ansel,James Ryan Mark,Lambros Stamatakis,Jean H. Hoffman-Censits,Rosalia Viterbo,Eric M. Horwitz,Mark A. Hallman,R. Katherine Alpaugh,Richard E. Greenberg,Marc C. Smaldone,Robert G. Uzzo,David Y.T. Chen,Alexander Kutikov,Elizabeth R. Plimack

A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): Interim analysis.

2021

397Background: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy (Cx) or chemoradiation (CRT) is the standard of care for urothelial carcinoma (UC) pts with muscle invasive blad...

Keywords:

Urology
Cisplatin
muscle invasive
Bladder cancer
standard of care
urothelial carcinoma
Interim analysis
Cystectomy
Medicine
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations